Leandro de Pádua Silva

Author

The University of Texas MD Anderson Cancer Center

Also Known As

Leandro De Padua Silva, Leandro de Padua Silva, Leandro de Padua silva, Leandro de Pádua Silva

Publications

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Hospital Sírio-Libanês University of Michigan

About

Leandro de Pádua Silva is an author at The University of Texas MD Anderson Cancer Center specializing in cell transplantation, blood transplantation, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	138
2	Blood Transplantation	3	3	138
3	Health Sciences	2	2	120
4	Immunology	2	2	45
5	Marrow Transplantation	2	2	111

Leandro de Pádua Silva

Publications

963

Citations

H-Index

Page 1

	Year	Citations
Maintenance therapy with low‐dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome Marcos de Lima, Sergio Giralt, Peter F. Thall, Cancer	2010	427
Phase I Study of Epigenetic Modulation with 5-Azacytidine and Valproic Acid in Patients with Advanced Cancers Fadi Braiteh, Andres O. Soriano, Guillermo Garcia‐Manero, Clinical Cancer Research	2008	163
Myeloablative Reduced-Toxicity i.v. Busulfan-Fludarabine and Allogeneic Hematopoietic Stem Cell Transplant for Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome in the Sixth through Eighth Decades of Life Gheath Alatrash, Marcos de Lima, Nelson Hamerschlak, Biology of Blood and Marrow Transplantation Mixed-phenotype Acute LeukemiaPharmacotherapyMyeloid NeoplasiaBu-flu Conditioning RegimensHematological Malignancy	2011	93
Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease Simrit Parmar, Marcos del Lima, Yizhou Zou, Blood	2009	82
Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD–Positive Acute Myelogenous Leukemia Betül Oran, Jörge E. Cortes, Amer Beitinjaneh, Biology of Blood and Marrow Transplantation	2016	81
Prophylaxis of Graft-Versus-Host Disease in Unrelated Donor Transplantation With Pentostatin, Tacrolimus, and Mini-Methotrexate: A Phase I/II Controlled, Adaptively Randomized Study Simrit Parmar, Börje S. Andersson, Daniel R. Couriel, Journal of Clinical Oncology	2010	28
Randomized phase II trial comparing two dose levels of thymoglobulin in patients undergoing unrelated donor hematopoietic cell transplant Qaiser Bashir, Mark F. Munsell, Sergio Giralt, Leukemia & lymphoma/Leukemia and lymphoma TransplantationPhase Ii TrialDose LevelsHematologyClinical Trials	2011	27
Resolved Hepatitis B Virus Infection Is Not Associated with Worse Outcome after Allogeneic Hematopoietic Stem Cell Transplantation Carlos A. Ramos, Rima M. Saliba, Leandro de Pádua Silva, Biology of Blood and Marrow Transplantation	2010	25
Double Cord Blood Transplantation (CBT) with and without Ex-Vivo Expansion (EXP): A Randomized, Controlled Study Marcos de Lima, Jonh D. McMannis, Rima M. Saliba, Blood	2008	19
Moderate Renal Function Impairment Does Not Affect Outcomes of Reduced-Intensity Conditioning with Fludarabine and Melphalan for Allogeneic Hematopoietic Stem Cell Transplantation Jonas A. de Souza, Rima M. Saliba, Poliana Patah, Biology of Blood and Marrow Transplantation Modified DietAffect OutcomesGfr Estimation MethodImmunologyNonrelapse Mortality	2009	18

Page 1